scholarly journals Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis

2009 ◽  
Vol 66 (1) ◽  
Author(s):  
Mark P. Gorman ◽  
Brian C. Healy ◽  
Mariann Polgar-Turcsanyi ◽  
Tanuja Chitnis
Keyword(s):  
Multiple Sclerosis ◽  
Relapse Rate ◽  
Adult Onset ◽  
Pediatric Onset

scholarly journals A Scoping Review of Modifiable Risk Factors in Pediatric Onset Multiple Sclerosis: Building for the Future

Children ◽  
2018 ◽  
Vol 5 (11) ◽  
pp. 146 ◽  
Author(s):  
Julie Pétrin ◽  
Max Fiander ◽  
Prenitha Doss ◽  
E. Yeh
Keyword(s):  
Physical Activity ◽  
Multiple Sclerosis ◽  
Vitamin D ◽  
Relapse Rate ◽  
Scoping Review ◽  
Full Text ◽  
Lifestyle Factors ◽  
Increased Risk ◽  
Modifiable Lifestyle Factors ◽  
Pediatric Onset

Knowledge of the effect of modifiable lifestyle factors in the pediatric multiple sclerosis (MS) population is limited. We therefore conducted a scoping review, following the framework provided by Arksey and O’Malley. Four databases were searched for pediatric MS and modifiable lifestyle factors using index terms and keywords, from inception to May 2018. All quantitative and qualitative primary articles were included and limited to English and full text. Of the 7202 articles identified and screened, 25 full-text articles were relevant to our objective and were included. These articles focused on diet obesity, physical activity, and sleep. In cross-sectional analyses, these lifestyle factors were associated with increased risk of pediatric onset MS (POMS), and increased disease activity. Diet, particularly vitamin D and vegetable intake, was associated with reduced relapse rate. Obesity was linked to increased risk of POMS, and physical activity was associated with reduced relapse rate and sleep/rest fatigue. Thus, available studies of lifestyle related outcomes in pediatric MS suggest specific lifestyle related factors, including obesity, higher vitamin D levels, and higher physical activity may associate with lower disease burden in POMS. Studies reviewed are limited by their observational designs. Future studies with longitudinal and experimental designs may further clarify the role of modifiable lifestyle factors in this population.

scholarly journals Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis

2019 ◽  
Vol 76 (9) ◽  
pp. 1028 ◽  
Author(s):  
Kyla A. McKay ◽  
Ali Manouchehrinia ◽  
Lindsay Berrigan ◽  
John D. Fisk ◽  
Tomas Olsson ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Outcomes ◽  
Adult Onset ◽  
Pediatric Onset

scholarly journals Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kyla A. McKay ◽  
Ronny Wickström ◽  
Jan Hillert ◽  
Virginija Danylaite Karrenbauer
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Relapse Rate ◽  
Negative Binomial ◽  
Negative Binomial Regression ◽  
Expanded Disability Status Scale ◽  
Binomial Regression ◽  
Disability Status ◽  
Igg Index ◽  
Pediatric Onset

AbstractTo investigate whether cerebrospinal fluid (CSF) markers differ between pediatric-onset multiple sclerosis (PoMS, onset < 18 years) and adult-onset (AoMS), and whether these markers are associated with clinical outcomes among PoMS. Prospective nationwide registry study of incident MS, including persons with a CSF sample < 3 years post-MS onset. We compared CSF oligoclonal band (OCB) status, immunoglobulin G (IgG) index levels, and mononuclear cell count between PoMS and AoMS. Within the PoMS cohort we analyzed the association between CSF markers, relapse rate and Expanded Disability Status Scale (EDSS) score, using negative binomial regression and generalized estimating equations, respectively. The cohort consisted of 130 PoMS and 3228 AoMS cases. The PoMS group had higher odds of OCB-positivity (odds ratio: 2.70; 95% CI 1.21–7.67). None of the CSF markers were associated with relapse rate in the PoMS cohort; however, OCB-positivity was associated with higher EDSS scores. This study suggested that PoMS more commonly display CSF evidence for intrathecal IgG production than AoMS. Further, we found evidence of a relationship between OCB-positivity and subsequent disability, suggesting that they could play a role in the prognostication of MS in children.

Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans

2016 ◽  
Vol 31 (8) ◽  
pp. 1068-1073 ◽  
Author(s):  
Megan M. Langille ◽  
Talat Islam ◽  
Margaret Burnett ◽  
Lilyana Amezcua
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Characteristics ◽  
Hispanic Americans ◽  
Adult Onset ◽  
Pediatric Onset

scholarly journals Inflammatory Activity and Treatment Response in Pediatric Compared to Adult Multiple Sclerosis: A Pilot, Retrospective and Observational Study of the First Year After Diagnosis

2020 ◽  
Vol 33 (13) ◽  
Author(s):  
Sara De Carvalho ◽  
Joana Pinto ◽  
Inês Correia ◽  
Ricardo Faustino ◽  
Mónica Vasconcelos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Small Sample ◽  
Inflammatory Activity ◽  
Adult Onset ◽  
Multiple Sclerosis Group ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
One Year ◽  
Pediatric Onset

Introduction: Pediatric-onset multiple sclerosis may contrast with adult-onset multiple sclerosis, in terms of disease activity. We aimed to determine differentiating features between pediatric-onset multiple sclerosis and adult-onset multiple sclerosis, at diagnosis and after one year under disease modifying therapies, and analyse the attainment of the status of “No Evidence of Disease Activity” between groups.Material and Methods: We analyzed demographical, laboratory, clinical and imaging features of patients with relapsing-remitting multiple sclerosis diagnosed at our center, according to the McDonald’s 2010 criteria, with ≥ 1 year under disease modifying therapies and with available magnetic resonance imaging scans at diagnosis and one year after disease modifying therapies initiation. Patients were paired according to gender and disease modifying therapies in use. “No Evidence of Disease Activity” status was assessed, and differences were studied.Results: Fifteen pediatric-onset multiple sclerosis (aged ≥ 8 and < 18 years) and 15 adult-onset multiple sclerosis (≥ 18 and < 55 years) patients were recruited. We found a statistically significant difference in the number of T2 weighted image diffuse lesions/with poorly defined borders (p = 0.015). The mean expanded disability status scale score after one year under disease modifying therapies was lower in the pediatric-onset multiple sclerosis group (1.6 ± 0.8) compared to the adult-onset multiple sclerosis group (2.3 ± 0.8; p = 0.032). Nevertheless, no differences were found regarding the percentage of cases achieving “No Evidence of Disease Activity” in either group.Discussion: Although there is an empirical impression about the difference in inflammatory activity between pediatric-onset multiple sclerosis and adult-onset multiple sclerosis, it was not possible to corroborate it in our study. Nevertheless, this was an exploratory and retrospective analysis of a small sample of patients, identifying variables in which such differences appear to be most important.Conclusion: Extensive studies of children, adolescents and adults with multiple sclerosis will be needed to categorize the clinical and radiological differences that allow the identification of drug response biomarkers in the early stages of the disease.

Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States

2009 ◽  
Vol 15 (5) ◽  
pp. 627-631 ◽  
Author(s):  
T Chitnis ◽  
B Glanz ◽  
S Jaffin ◽  
B Healy
Keyword(s):  
United States ◽  
Multiple Sclerosis ◽  
The United States ◽  
Adult Onset ◽  
Electronic Database ◽  
Northeastern United States ◽  
Disease Characteristics ◽  
Patients Experience ◽  
Pediatric Onset

Background The prevalence of pediatric-onset multiple sclerosis (MS) in the United States is unknown. Objective In a large cohort of MS patients, we sought to identify the proportion with first symptom-onset below the age of 18 years, and to compare their demographic and disease characteristics to a typical adult-onset MS population. Methods Patients seen at the Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Boston, Massachusetts, with clinical histories and characteristics of first symptoms recorded in an electronic database, were included in this study. Results We found that 3.06% of patients with a recorded MS history experienced a first attack under the age of 18 years of age compared to 30.83% of patients who experienced first symptoms between the ages of 25–35 years. Gender proportions were similar in both groups, with the exception of a lower female preponderance in pre-pubertal-onset patients. There was a higher proportion of non-Caucasians in the younger cohort. Localization of first symptoms was similar in the two groups. Conclusion About 3% of MS patients experience their first symptom prior to the age of 18 years. Standardized follow-up is required after a first demyelinating attack in childhood, which may lead to earlier diagnosis and treatment of pediatric-onset MS.

Sign in / Sign up

Export Citation Format

Share Document